Trials / Unknown
UnknownNCT06253429
Alpha-lipoic Acid in Diabetic Nephropathy
Oxidative Stress in Children and Adolescents With Diabetic Nephropathy and the Role of Adjuvant Alpha-lipoic Acid as an Antioxidant
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 6 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Endothelial dysfunction in diabetes is a central event in the pathogenesis of different microangioapthic changes. Nephropathy in patients with type 1 diabetes is a severe microvascular complication.
Detailed description
Better understanding of the pathogenesis of microvascular complications in type 1 diabetes have paved the way for novel therapeutic targets and possible adjuvant therapeutic modalities. Oxidative stress is considered a common and important factor that links hyperglycemia with the vascular complications in diabetes, including of diabetic nephropathy (DN). Alpha lipoic acid (ALA), or thioctacid, is an antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes. ALA can scavenge free radicals, activate antioxidant systems, and also affect inflammatory markers. It also has unique characteristic. ALA can play as a reduction for oxidized forms of components with antioxidant properties and neutralize reactive oxygen species. Thus, it called as antioxidant of antioxidants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thioctic Acid 333 MG Oral Capsule | Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes |
| DRUG | Captopril 25Mg Tab | Oral angiotensin-converting enzyme inhibitors |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2024-01-31
- Completion
- 2024-02-01
- First posted
- 2024-02-12
- Last updated
- 2024-02-12
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06253429. Inclusion in this directory is not an endorsement.